Rinat Rotem-Yehudar

Rinat Rotem-Yehudar

UNVERIFIED PROFILE

Are you Rinat Rotem-Yehudar?   Register this Author

Register author
Rinat Rotem-Yehudar

Rinat Rotem-Yehudar

Publications by authors named "Rinat Rotem-Yehudar"

Are you Rinat Rotem-Yehudar?   Register this Author

9Publications

253Reads

18Profile Views

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.

J Clin Oncol 2013 Nov 14;31(33):4199-206. Epub 2013 Oct 14.

Philippe Armand and Edie Weller, Dana-Farber Cancer Institute; David E. Avigan, Beth Israel Deaconess Medical Center; Yi-Bin Chen, Massachusetts General Hospital, Boston, MA; Arnon Nagler, Chaim Sheba Medical Center, Tel-Hashomer; Reuven Or, Hadassah Medical Center, Jerusalem; Rinat Rotem-Yehudar, CureTech, Yavne, Israel; Steven M. Devine, The Ohio State University Comprehensive Cancer Center, Ohio State University, Columbus; Hillard M. Lazarus, Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, OH; Mark S. Kaminski, University of Michigan, Ann Arbor, MI; H. Kent Holland, Northside Hospital; Edmund K. Waller, Winship Cancer Institute, Emory University, Atlanta, GA; Jane N. Winter and Leo I. Gordon, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine; Stephanie A. Gregory, Rush Medical Center, Chicago, IL; James R. Mason, Scripps Clinic; Edward D. Ball, Moores University of California at San Diego Cancer Center, University of California, San Diego; John M. Timmerman and David Andorsky, University of California, Los Angeles, Los Angeles, CA; Joseph W. Fay, Baylor Research Institute, Baylor University Medical Center, Dallas; Chitra M. Hosing, The University of Texas MD Anderson Cancer Center, Houston, TX; David A. Rizzieri, Duke Cancer Center, Durham, NC; Joseph P. Uberti, Karmanos Cancer Institute, Detroit, MI; Markus Y. Mapara, University of Pittsburgh School of Medicine and Cancer Institute, Pittsburgh, PA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2012.48.3685
Publisher Site
http://dx.doi.org/10.1200/JCO.2012.48.3685DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878008PMC
November 2013

Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms.

Eur J Immunol 2011 Oct 17;41(10):2977-86. Epub 2011 Aug 17.

Cancer Vaccine Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/eji.201141639DOI Listing
October 2011

Transferrin [corrected] receptor association and endosomal localization of soluble HFE are not sufficient for regulation of cellular iron homeostasis.

J Cell Biochem 2004 Apr;91(6):1130-45

Department of Cell Research and Immunology, Tel Aviv University, Ramat Aviv 69978, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.20015DOI Listing
April 2004

EHD3: a protein that resides in recycling tubular and vesicular membrane structures and interacts with EHD1.

Traffic 2002 Aug;3(8):575-89

Department of Cell Research and Immunology, Tel-Aviv University, Ramat-Aviv, Israel 69978.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1034/j.1600-0854.2002.30807.xDOI Listing
August 2002